Boston, MA – Longboard Pharmaceuticals, Inc. hosted its Q2 2024 Earnings Call Transcript on August 1, 2024, at 4:30 PM ET. The call featured key Company Participants including Brandi Roberts, the Executive Vice President and Chief Financial Officer, Kevin Lind, the President and Chief Executive Officer, and Randall Kaye, the Executive Vice President and Chief Medical Officer. Additionally, several Conference Call Participants from prominent financial institutions were part of the discussion.

During the call, Brandi Roberts provided an overview of Longboard’s corporate update, focusing on the results from their LP659 single-ascending dose study. The discussion included forward-looking statements about product candidates, clinical trials, commercial opportunities, and financial guidance. Kevin Lind, the President and CEO, highlighted the accomplishments of Longboard in 2024, specifically focusing on the success of Bexicaserincaserin in treating developmental and epileptic encephalopathies (DEEs). This included positive data from their PACIFIC study and obtaining breakthrough therapy designation for seizures associated with DEEs.

The company expressed its commitment to addressing the unmet medical needs of patients with DEEs, emphasizing the importance of their Phase 3 program. Furthermore, Longboard provided insights into their second clinical stage asset, LP659, a highly selective S1P receptor modulator, showcasing its potential in treating various orphan neurological disorders such as multiple sclerosis.

Randall Kaye discussed the functionality of LP659 in selectively modulating S1PR1, emphasizing its potential impact on reducing inflammation and promoting neuroprotection in the central nervous system. The discussion extended to the Phase 1 SAD trial and its positive safety profile.

In the Q&A session, participants inquired about Longboard’s regulatory alignment, indication selection process, food effect observations, harmonizing endpoints across DEEs, and the status of the partial clinical hold on the S1P molecule. Longboard’s executives provided detailed responses, highlighting their strategic approach to addressing these challenges and opportunities.

The call concluded with closing remarks from Kevin Lind, expressing gratitude for the participation and enthusiasm surrounding Longboard’s innovative developments. Participants were encouraged to stay informed about the company’s progress and future endeavors.

Overall, Longboard Pharmaceuticals, Inc. showcased its dedication to advancing groundbreaking treatments for neurological disorders, setting a path for transformative healthcare solutions.